Advertisement
UK markets close in 1 hour 3 minutes
  • FTSE 100

    7,861.18
    -15.87 (-0.20%)
     
  • FTSE 250

    19,342.69
    -107.98 (-0.56%)
     
  • AIM

    744.09
    -1.20 (-0.16%)
     
  • GBP/EUR

    1.1668
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.2454
    +0.0015 (+0.12%)
     
  • Bitcoin GBP

    51,841.62
    +696.05 (+1.36%)
     
  • CMC Crypto 200

    1,380.60
    +67.98 (+5.47%)
     
  • S&P 500

    4,991.92
    -19.20 (-0.38%)
     
  • DOW

    37,883.42
    +108.04 (+0.29%)
     
  • CRUDE OIL

    82.91
    +0.18 (+0.22%)
     
  • GOLD FUTURES

    2,401.00
    +3.00 (+0.13%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,736.33
    -101.07 (-0.57%)
     
  • CAC 40

    8,027.48
    +4.22 (+0.05%)
     

FTSE finishes higher, Hikma and GlaxoSmithKline boost

* Blue-chip FTSE 100 index ends 1.2 pct higher

* GlaxoSmithKline (Other OTC: GLAXF - news) , Barclays (LSE: BARC.L - news) , British American Tobacco up

* Quintain Estates and Development (LSE: QED.L - news) surges 22 pct

By Atul Prakash

LONDON, July 29 (Reuters) - Britain's top share index advanced on Wednesday, with Hikma Pharmaceuticals (LSE: HIK.L - news) leading the market higher on positive broker comments and GlaxoSmithKline (Amsterdam: GO8.AS - news) gaining after reporting a lower-than-expected fall in quarterly earnings.

Hikma shares were the biggest blue-chip gainers after a target price update from Jefferies, adding 3.7 percent to an 11.6 percent jump on Tuesday, when it announced a deal to buy Boehringer Ingelheim's U.S. generic drugs business Roxane for about $2.65 billion in cash and stock.

ADVERTISEMENT

"The deal has created a firm foundation for future growth," said Augustin Eden, analyst at Accendo Markets. "Hikma shares could be bound for a return to February highs and above - still a healthy 8.5 percent away despite gains of yesterday."

The blue-chip FTSE 100 index closed 1.2 percent higher at 6,631.00 points after rising 0.8 percent in the previous session, when it snapped a five-day losing streak.

Drugmaker GlaxoSmithKline gained 3.5 percent after flagging up dozens of new drugs and vaccines in development as demand for new HIV medicines helped it beat quarterly profit forecasts.

Barclays shares were up nearly 2 percent after the bank, which reported a 12 percent rise in profit, said it intended to accelerate the sale of assets and cost cutting.

"Barclays appears eager to press ahead with the increased pace of restructuring ... Most of the key metrics continue to show improvement, with a reduction in operating expenses and impairments being complemented by another robust income showing, leading to a notable hike in adjusted profits," said Richard Hunter, head of equities at Hargreaves Lansdown (LSE: HL.L - news) .

"In addition, the capital cushion remains comfortable and the return on equity is showing some signs of life."

British American Tobacco advanced 3.6 percent after reporting a better-than-expected performance for the second quarter.

Small-cap Quintain Estates and Development jumped 22 percent on news that it is to be bought by U.S. private equity firm Lone Star after receiving a bid valuing the firm at around 700 million pounds ($1.1 billion)..

On the downside, Compass Group (Other OTC: CMPGF - news) , the world's biggest catering firm, fell 5.3 percent after saying operating profit this year and next would be hit by restructuring costs.

Mid-cap engineering supply group Premier Farnell (LSE: PFL.L - news) slumped 16 percent following comments that it expected a 10 percent fall in first-half adjusted operating profit after sales growth per day in its main markets slowed in the second quarter. (Additional reporting by Liisa Tuhkanen; Editing by Alison Williams and Kevin Liffey)